Skip to main content
Top
Published in: Journal of Endocrinological Investigation 1/2016

01-01-2016 | Original Article

Coagulation parameters and platelet function analysis in patients with acromegaly

Authors: A. Colak, H. Yılmaz, Y. Temel, M. Demirpence, N. Simsek, İ. Karademirci, U. Bozkurt, E. Yasar

Published in: Journal of Endocrinological Investigation | Issue 1/2016

Login to get access

Abstract

Objective

Acromegaly is associated with increased cardiovascular morbidity and mortality. The data about the evaluation of coagulation and fibrinolysis in acromegalic patients are very limited and to our knowledge, platelet function analysis has never been investigated. So, we aimed to investigate the levels of protein C, protein S, fibrinogen, antithrombin 3 and platelet function analysis in patients with acromegaly.

Methods

Thirty-nine patients with active acromegaly and 35 healthy subjects were included in the study. Plasma glucose and lipid profile, fibrinogen levels, GH and IGF-1 levels and protein C, protein S and antithrombin III activities were measured in all study subjects. Also, platelet function analysis was evaluated with collagen/ADP and collagen–epinephrine-closure times.

Results

Demographic characteristics of the patient and the control were similar. As expected, fasting blood glucose levels and serum GH and IGF-1 levels were significantly higher in the patient group compared with the control group (pglc: 0.002, pGH: 0.006, pIGF-1: 0.001, respectively). But lipid parameters were similar between the two groups. While serum fibrinogen and antithrombin III levels were found to be significantly higher in acromegaly group (p fibrinogen: 0.005 and pantithrombin III: 0.001), protein S and protein C activity values were significantly lower in the patient group (p protein S: 0.001, p protein C: 0.001). Also significantly enhanced platelet function (measured by collagen/ADP- and collagen/epinephrine-closure times) was demonstrated in acromegaly (p col-ADP: 0.002, p col-epinephrine: 0.002). The results did not change, when we excluded six patients with type 2 diabetes in the acromegaly group. There was a negative correlation between serum GH levels and protein S (r: –0.25, p: 0.04)) and protein C (r: –0.26, p: 0.04) values. Likewise, there was a negative correlation between IGF-1 levels and protein C values (r: –0.39, p: 0.002), protein S values (r: –0.39, p: 0.001), collagen/ADP-closure times (r: –0.28, p: 0.02) and collagen/epinephrine-closure times (r:-0.26, p: 0.04). Also, we observed a positive correlation between IGF-1 levels and fibrinogen levels (r: 0.31, p: 0.01).

Conclusion

Acromegaly was found to be associated with increased tendency to coagulation and enhanced platelet activity. This hypercoagulable state might increase the risk for cardiovascular and cerebrovascular events in acromegaly.
Literature
1.
go back to reference Vilar L, Naves LA, Costa SS, Abdalla LF, Coelho CE, Casulari LA (2007) Increase of classic and nonclassic cardiovascular risk factors in patients with acromegaly. Endocr Pract 13(4):363–372CrossRefPubMed Vilar L, Naves LA, Costa SS, Abdalla LF, Coelho CE, Casulari LA (2007) Increase of classic and nonclassic cardiovascular risk factors in patients with acromegaly. Endocr Pract 13(4):363–372CrossRefPubMed
2.
go back to reference Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK (1994) Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 41(1):95–102CrossRef Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK (1994) Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 41(1):95–102CrossRef
3.
go back to reference Jurcut R, Găloiu S, Florian A, Vlădaia A, Ioniţă OR, Amzulescu MS, et al (2014) Quantifying subtle changes in cardiovascular mechanics in acromegaly: a Doppler myocardial imaging study. J Endocrinol Invest 37:1081–1090CrossRefPubMed Jurcut R, Găloiu S, Florian A, Vlădaia A, Ioniţă OR, Amzulescu MS, et al (2014) Quantifying subtle changes in cardiovascular mechanics in acromegaly: a Doppler myocardial imaging study. J Endocrinol Invest 37:1081–1090CrossRefPubMed
4.
go back to reference Wildbrett J, Hanefeld M, Fücker K, Pinzer T, Bergmann S, Siegert G, Breidert M (1997) Anomalies of lipoprotein pattern and fibrinolysis in acromegalic patients: relation to growth hormone levels and insulin-like growth factor I. Exp Clin Endocrinol Diabetes 105(6):331–335CrossRefPubMed Wildbrett J, Hanefeld M, Fücker K, Pinzer T, Bergmann S, Siegert G, Breidert M (1997) Anomalies of lipoprotein pattern and fibrinolysis in acromegalic patients: relation to growth hormone levels and insulin-like growth factor I. Exp Clin Endocrinol Diabetes 105(6):331–335CrossRefPubMed
5.
go back to reference Colao A, Marzullo P, Di Somma C, Lombardi G (2001) Growth hormone and the heart. Clin Endocrinol (Oxf). 54(2):137–154CrossRefPubMed Colao A, Marzullo P, Di Somma C, Lombardi G (2001) Growth hormone and the heart. Clin Endocrinol (Oxf). 54(2):137–154CrossRefPubMed
6.
go back to reference Erem C, Nuhoglu I, Kocak M, Yilmaz M, Sipahi ST, Ucuncu O, Ersoz HO (2008) Blood coagulation and fibrinolysis in patients with acromegaly: increased plasminogen activator inhibitor-1 (PAI-1), decreased tissue factor pathway inhibitor (TFPI), and an inverse correlation between growth hormone and TFPI. Endocrine 33(3):270–276. doi:10.1007/s12020-008-9088-4 CrossRefPubMed Erem C, Nuhoglu I, Kocak M, Yilmaz M, Sipahi ST, Ucuncu O, Ersoz HO (2008) Blood coagulation and fibrinolysis in patients with acromegaly: increased plasminogen activator inhibitor-1 (PAI-1), decreased tissue factor pathway inhibitor (TFPI), and an inverse correlation between growth hormone and TFPI. Endocrine 33(3):270–276. doi:10.​1007/​s12020-008-9088-4 CrossRefPubMed
7.
go back to reference Delaroudis SP, Efstathiadou ZA, Koukoulis GN, Kita MD, Farmakiotis D, Dara OG et al (2008) Amelioration of cardiovascular risk factors with partial biochemical control of acromegaly. Clin Endocrinol (Oxf) 69(2):279–284CrossRef Delaroudis SP, Efstathiadou ZA, Koukoulis GN, Kita MD, Farmakiotis D, Dara OG et al (2008) Amelioration of cardiovascular risk factors with partial biochemical control of acromegaly. Clin Endocrinol (Oxf) 69(2):279–284CrossRef
8.
go back to reference Landin-Wilhelmsen K, Tengborn L, Wilhelmsen L, Bengtsson BA (1997) Elevated fibrinogen levels decrease following treatment of acromegaly. Clin Endocrinol (Oxf) 46(1):69–74CrossRef Landin-Wilhelmsen K, Tengborn L, Wilhelmsen L, Bengtsson BA (1997) Elevated fibrinogen levels decrease following treatment of acromegaly. Clin Endocrinol (Oxf) 46(1):69–74CrossRef
9.
go back to reference Sartorio A, Cattaneo M, Bucciarelli P, Bottasso B, Porretti S, Epaminonda P, Faglia G, Arosio M (2000) Alterations of haemostatic and fibrinolytic markers in adult patients with growth hormone deficiency and with acromegaly. Exp Clin Endocrinol Diabetes 108(7):486–492CrossRefPubMed Sartorio A, Cattaneo M, Bucciarelli P, Bottasso B, Porretti S, Epaminonda P, Faglia G, Arosio M (2000) Alterations of haemostatic and fibrinolytic markers in adult patients with growth hormone deficiency and with acromegaly. Exp Clin Endocrinol Diabetes 108(7):486–492CrossRefPubMed
10.
go back to reference Harrison P, Mackie I, Mathur A, Robinson MS, Hong Y, Erusalimsky JD, Machin SJ, Martin JF (2005) Platelet hyper-function in acute coronary syndromes. Blood Coagul Fibrinolysis 16(8):557–562CrossRefPubMed Harrison P, Mackie I, Mathur A, Robinson MS, Hong Y, Erusalimsky JD, Machin SJ, Martin JF (2005) Platelet hyper-function in acute coronary syndromes. Blood Coagul Fibrinolysis 16(8):557–562CrossRefPubMed
11.
go back to reference Frossard M, Fuchs I, Leitner JM, Hsieh K, Vlcek M, Losert H, Domanovits H et al (2004) Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation 110(11):1392–1397 Epub 2004 Aug 16 CrossRefPubMed Frossard M, Fuchs I, Leitner JM, Hsieh K, Vlcek M, Losert H, Domanovits H et al (2004) Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation 110(11):1392–1397 Epub 2004 Aug 16 CrossRefPubMed
13.
go back to reference Jilma B (2001) Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired dysfunction. J Lab Clin Med 138:152–163CrossRefPubMed Jilma B (2001) Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired dysfunction. J Lab Clin Med 138:152–163CrossRefPubMed
14.
go back to reference Renda G, Zurro M, Malatesta G, Ruggieri B, De Caterina R (2010) Inconsistency of different methods for assessing ex vivo platelet function: relevance for the detection of aspirin resistance. Haematol 95(12):2095–2101CrossRef Renda G, Zurro M, Malatesta G, Ruggieri B, De Caterina R (2010) Inconsistency of different methods for assessing ex vivo platelet function: relevance for the detection of aspirin resistance. Haematol 95(12):2095–2101CrossRef
15.
go back to reference Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, Wass JA (2014) Endocrine Society. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933–3951CrossRefPubMed Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, Wass JA (2014) Endocrine Society. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933–3951CrossRefPubMed
16.
go back to reference Mestron A, Webb SM, Astorga R, Benito P, Catala M, Gaztambide S et al (2004) Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol 151(4):439–446CrossRefPubMed Mestron A, Webb SM, Astorga R, Benito P, Catala M, Gaztambide S et al (2004) Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol 151(4):439–446CrossRefPubMed
17.
go back to reference Arosio M, Reimondo G, Malchiodi E, Berchialla P, Borraccino A, De Marinis L, Italian Study Group of Acromegaly et al (2012) Predictors of morbidity and mortality in acromegaly: an Italian survey. Eur J Endocrinol 167(2):189–198PubMed Arosio M, Reimondo G, Malchiodi E, Berchialla P, Borraccino A, De Marinis L, Italian Study Group of Acromegaly et al (2012) Predictors of morbidity and mortality in acromegaly: an Italian survey. Eur J Endocrinol 167(2):189–198PubMed
18.
go back to reference Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25(1):102–152CrossRefPubMed Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25(1):102–152CrossRefPubMed
19.
go back to reference Feinbloom D, Bauer KA (2005) Assessment of hemostatic risk factors in predicting arterial thrombotic events. Arterioscler Thromb Vasc Biol 25(10):2043–2053CrossRefPubMed Feinbloom D, Bauer KA (2005) Assessment of hemostatic risk factors in predicting arterial thrombotic events. Arterioscler Thromb Vasc Biol 25(10):2043–2053CrossRefPubMed
20.
go back to reference Vitale G, Pivonello R, Galderisi M, D’Errico A, Spinelli L, Lupoli G, Lombardi G, Colao A (2001) Cardiovascular complications in acromegaly: methods of assessment. Pituit 4(4):251–257CrossRef Vitale G, Pivonello R, Galderisi M, D’Errico A, Spinelli L, Lupoli G, Lombardi G, Colao A (2001) Cardiovascular complications in acromegaly: methods of assessment. Pituit 4(4):251–257CrossRef
21.
go back to reference Dahlbäck B, Villoutreix BO (2005) The anticoagulant protein C pathway. FEBS Lett 579(15):3310–3316CrossRefPubMed Dahlbäck B, Villoutreix BO (2005) The anticoagulant protein C pathway. FEBS Lett 579(15):3310–3316CrossRefPubMed
Metadata
Title
Coagulation parameters and platelet function analysis in patients with acromegaly
Authors
A. Colak
H. Yılmaz
Y. Temel
M. Demirpence
N. Simsek
İ. Karademirci
U. Bozkurt
E. Yasar
Publication date
01-01-2016
Publisher
Springer International Publishing
Published in
Journal of Endocrinological Investigation / Issue 1/2016
Electronic ISSN: 1720-8386
DOI
https://doi.org/10.1007/s40618-015-0300-0

Other articles of this Issue 1/2016

Journal of Endocrinological Investigation 1/2016 Go to the issue

Thanks to Reviewers

Thanks to Reviewers 2015

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine